| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 12, 2025 | ANIP Ani Pharmaceuticals Inc | Carey Stephen P.55 | SVP &CFO | Sell | 50,000 | $86.07 | $4,303,500.00 | -21.7% | +0.7% | - | |
| Aug 12, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Shah Nikita53 | Executive Vice President | Sell | 50,000 | $9.04 | $452,000.00 | -12.9% | +27.3% | - | |
| Aug 12, 2025 | LLY Eli Lilly & Co | Skovronsky Daniel | EVP, CSO &Pres. Lrl &Lly Imm | Buy | 1,000 | $634.41 | $634,405.00 | +0.7% | +51.2% | - | |
| Aug 12, 2025 | ANIP Ani Pharmaceuticals Inc | Haughey Thomas | Director | Sell | 19,341 | $85.93 | $1,661,972.13 | -34.6% | +0.7% | - | |
| Aug 12, 2025 | ANIP Ani Pharmaceuticals Inc | Gutwerg Ori47 | SVP, Generics | Sell | 5,873 | $86.53 | $508,190.69 | -6.5% | +0.7% | - | |
| Aug 12, 2025 | ANIP Ani Pharmaceuticals Inc | Rowland Thomas Andrew | SVP, Head - Established Brands | Sell | 4,975 | $85.71 | $426,407.25 | -10.9% | +0.7% | - | |
| Aug 12, 2025 | AMRX Amneal Pharmaceuticals, Inc. | Daly Jason B. | EVP, Chief Legal Officer | Sell | 22,000 | $9.05 | $199,100.00 | -67.5% | +27.3% | - | |
| Aug 12, 2025 | EBS Emergent Biosolutions Inc. | Degolyer Donald W54 | Director | Sell | 7,844 | $8.65 | $67,830.99 | -5.4% | +23.3% | - | |
| Aug 12, 2025 | LLY Eli Lilly & Co | Sulzberger Gabrielle | Director | Buy | 117 | $641.18 | $75,018.29 | +4.5% | +51.2% | - | |
| Aug 11, 2025 | IRWD Ironwood Pharmaceuticals Inc | John Minardo69 | Chief Legal Officer | Sell | 7,754 | $0.84 | $6,513.36 | -1.9% | +202.5% | - | |
| Aug 11, 2025 | IRWD Ironwood Pharmaceuticals Inc | Martini Gregory S. | Chief Financial Officer | Sell | 1,265 | $0.84 | $1,062.60 | -0.7% | +202.5% | - | |
| Aug 11, 2025 | IRWD Ironwood Pharmaceuticals Inc | Silver Ronald68 | Principal Accounting Officer | Sell | 2,846 | $0.84 | $2,390.64 | -1.0% | +202.5% | - | |
| Aug 11, 2025 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 2,572 | $51.64 | $132,818.08 | -1.7% | -17.9% | - | |
| Aug 11, 2025 | LLY Eli Lilly & Co | Yuffa Ilya | EVP&Pres, Lly Usa&Global Capab | Sell | 1,250 | $627.01 | $783,762.50 | -4.5% | +52.2% | - | |
| Aug 11, 2025 | IRWD Ironwood Pharmaceuticals Inc | Gaskins Tammi L | Chief Commercial Officer | Sell | 1,316 | $0.84 | $1,105.44 | -0.5% | +202.5% | - | |
| Aug 8, 2025 | COLL Collegium Pharmaceutical, Inc | Freund John Gordon79 | Director | Sell | 11,659 | $34.36 | $400,640.55 | -33.5% | +16.4% | - | |
| Aug 8, 2025 | PRGO Perrigo Co Plc | Lockwood-Taylor Patrick48 | CEO | Buy | 4,460 | $22.37 | $99,766.35 | +1.8% | -33.8% | - | |
| Aug 8, 2025 | LLY Eli Lilly & Co | Jackson Jamere63 | Director | Buy | 200 | $639.56 | $127,912.60 | +2.2% | +49.8% | - | |
| Aug 7, 2025 | HIMS Hims & Hers Health, Inc. | Dudum Andrew47 | Chief Executive Officer | Sell | 660,000 | $50.58 | $33,384,120.00 | -23.0% | -14.3% | - | |
| Aug 7, 2025 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles56 | Director | Sell | 106,322 | $126.41 | $13,440,280.97 | -17.1% | +22.4% | - | |
| Aug 7, 2025 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 11,000 | $300.00 | $3,299,980.68 | -3.7% | +49.4% | - | |
| Aug 7, 2025 | PCRX Pacira Biosciences, Inc. | Bigal Marcelo82 | Director | Sell | 4,912 | $23.67 | $116,267.04 | -30.1% | -8.1% | - | |
| Aug 6, 2025 | HIMS Hims & Hers Health, Inc. | Carroll Patrick Harrison52 | Chief Medical Officer | Sell | 60,000 | $53.58 | $3,214,878.00 | -26.1% | -16.3% | - | |
| Aug 6, 2025 | KNSA Kiniksa Pharmaceuticals International, Plc | Paolini John F.51 | Chief Medical Officer | Sell | 29,325 | $32.55 | $954,528.75 | -33.8% | +17.8% | - | |
| Aug 6, 2025 | SUPN Supernus Pharmaceuticals, Inc. | Khattar Jack A.64 | President, CEO | Sell | 140,000 | $42.02 | $5,883,360.00 | -4.3% | +34.3% | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.